BioTech

Cocrystal’s Proprietary Technologies in Antiviral Therapeutics to Combat COVID-19

Published

Cocrystal interim Co-CEO James Martin discusses Cocrystal’s proprietary technologies in antiviral therapeutics to combat COVID-19 and other global health crises.

Nasdaq Watch

See what's playing at Nasdaq

Watch Now